Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330954 · ClinicalTrials.gov registry record
Gene Expression Profiling in Type 1 Diabetes
A clinical trial of Type 1 Diabetes Mellitus, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT00330954 is a study of Type 1 Diabetes Mellitus that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 64 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00330954, a study of Type 1 Diabetes Mellitus, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.
Conditions Studied
Study Locations (1)
Missouri
- Children's Mercy Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330954
The ClinicalTrials.gov registry entry for NCT00330954 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (54% lower). The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT00330954 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00330954 about?
NCT00330954 is a clinical study titled "Gene Expression Profiling in Type 1 Diabetes". One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitori...
What is the current status of trial NCT00330954?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2006-06. Estimated completion is 2008-04.
What conditions does trial NCT00330954 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
Who is sponsoring clinical trial NCT00330954?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00330954 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.